Detection of micrometastases by flow cytometry in sentinel lymph nodes from patients with renal tumours

Ciputra Adijaya Hartana, Johan Kinn, Robert Rosenblatt, Stefan Anania, Farhood Alamdari, Hans Glise, Amir Sherif and Ola Winqvist

1Karolinska Institutet, Department of Medicine Solna, Unit of Immunology and Allergy, Karolinska University Hospital, 171 76 Stockholm, Sweden; 2Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, 901 85 Umeå, Sweden; 3Department of Urology, Stockholm South General Hospital, Karolinska Institutet, Stockholm, Sweden and 4Department of Urology, Västmanland Hospital, Västerås, Sweden

**Background:** Stage is an important prognostic factor in renal tumours and dissemination to regional lymph nodes is associated with poor outcomes. Lymph nodes are routinely assessed by immunohistochemistry and microscopic evaluation, a time-consuming process where micrometastases might go undiagnosed. We evaluate an alternative method for detecting metastatic cells in sentinel nodes (SNs) by flow cytometry.

**Methods:** A total of 15 nodes from 5 patients diagnosed with renal tumours were analysed by flow cytometry. Staining for the intracellular marker cytokeratin 18 (CK18) with the surface markers carbonic anhydrase IX (CA9) and Cadherin 6 were used in flow cytometry analysis. Peripheral blood mononuclear cells (PBMCs) with the addition of known concentrations of cancer cell lines were analysed to investigate the sensitivity of micrometastasis detection.

**Results:** Stability of the assay was marked by low intra-assay variability (coefficient of variance ≤ 16%) and low inter-assay variability ($R^2 = 0.9996–1$). Eight nodes in four patients were positive for metastasis; six of them were considered being micrometastatic. These metastases were undetected by routine pathology and the patients were restaged from pN0 to pN1.

**Conclusions:** Flow cytometry is able to detect micrometastases in lymph nodes of renal tumour patients that were undetected under H&E examination.
can thus be increased by examining additional sections from every node (Lim et al, 2013), but this approach is too labour intensive for routine use when a large amount of nodes should be examined. In addition, MICs can potentially still be missed as only 5 μm thick sections of the whole lymph node are routinely examined, representing less than ~0.1% of the node.

Several attempts have been made to use alternative techniques to investigate the presence of metastatic cells in lymph nodes. Metastatic cells can be detected using reversed transcriptase-PCR (RT–PCR) (Haince et al, 2010). The method is highly sensitive, but mRNA is sensitive to degradation during storage and transportation (Weigelt et al, 2004). This induces the risk of receiving false negative results. In addition, some genes are upregulated during storage, thus generating false positive results (Benoy et al, 2006). Moreover, contamination may possess a problem in routine practice when multiple samples are handled in parallel, as RT–PCR detects very low levels of transcripts.

Flow cytometry has the ability to detect several parameters at the single-cell level. These multiple parameters may be analysed in combination with size (forward scatter) and complexity (side scatter) properties of each tumour cell studied. Tumour cells can also be detected by labelling of cytokeratin with fluorophore-conjugated antibodies, and labelling of DNA with propidium iodide (PI) (Leers et al, 2002).

We have recently described a method for detecting colon cancer cells in single-cell suspensions derived from lymph nodes by staining with multiple surface markers and detection by flow cytometry (Karlsson et al, 2008). In this method, we combine the staining method for intracellular and surface tumour antigens. Staining of intracellular markers is more cumbersome and may increase background. However, staining of surface markers has some limitations. Surface markers may be sensitive to enzymatic degradation that is a part of protocols to obtain single-cell suspensions. In addition, the expression of surface antigens may be downregulated because of genetic instability of tumour cells, as previously observed (Karlsson et al, 2008).

The differential expression of intracellular antigen, cytokeratin in various types of carcinomas makes them useful staining targets for IHC to identify tumour cells, a practice widely used for different subtypes. Surface markers of RCCs express varying patterns of cytokeratins (Langner et al, 2004), but staining for cytokeratin 18 (CK18) is the most commonly used for routine IHC evaluation of RCC (Messai et al, 2010). Surface markers can potentially also be used to identify renal tumour cells. The expression of carbonic anhydrase 9 (CA9), also known as G250 or MN, is highly prevalent in RCC, and the expression is considered as a prognostic factor (Soyupak et al, 2005). This surface antigen can readily be detected by flow cytometry (Li et al, 2001). Cadherin 6, a cell adhesion molecule found in the cell surface, is frequently used in conventional RCC (Li et al, 2005), and is also suggested as a new prognostic factor in RCC (Marshall, 2005).

An alternative method to evaluate the presence of metastases within lymph nodes needs to be developed. We therefore set up an experiment to detect metastatic cells of renal tumours by flow cytometry by combining a surface staining of CA9, Cadherin 6, and intracellular staining of CK18. In this study, we analysed 15 nodes from patients diagnosed with renal tumours with different pathological characteristics.
events were collected. Gating was set to exclude cell debris, as determined by forward and side scatter properties on a density plot. Positive events were identified in dot plots of fluorescence vs SSC properties for each marker respectively and displayed on a log-scale. The definite percentages of positive cells were calculated from percentage of positive cells deducted from background percentages acquired by isotype control.

RESULTS

Detection of tumour cell markers of RCC. We investigated three different RCC cell lines, RCC4, ACHN3, and CAKI6, for the expression of CK18, CA9, and Cadherin 6 by flow cytometry. The cell line RCC4 stained highly positive for CK18 and CA9 (Figure 1). However, the staining of Cadherin 6 showed a more continuous pattern, thus resulting in a less clear separation of positive events (Figure 1). However, when analysed in dot plots, >90% of RCC4 cells could be identified as positive for Cadherin 6 (data not shown).

Regarding the renal cancer cell lines ACHN3 and CAKI6, they stained highly positive for CK18 (Figure 1). However, none of these cell lines demonstrated expression of CA9 and Cadherin 6 (Figure 1).

Thus, we conclude that the intracellular marker CK18 is expressed at high levels in all three cell lines and that the cell surface markers CA9 and Cadherin 6 are expressed to a variable extent.

Detection of RCC cells in a mixed leukocyte environment. In order to test whether RCC cells could be detected by flow cytometry in a mixed environment of leukocytes using specific antibodies, we simulated the environment in a lymph node by adding decreasing numbers of renal cancer cells into PBMCs. The percentages of positive cells in each samples showed that all three markers CK18, CA9, and Cadherin 6 could be detected from 1% to 0.011% of added RCC4 cancer cell line with low background staining (Figure 2A). The percentages of added compared with the number of detected cells were analysed by regression analysis where regression coefficients above 0.97 indicate a linear and reliable detection of the three markers CK18, CA9, and Cadherin 6 from 0.011 to 1% added RCC4 cells (Figure 3).

When ACHN3 and CAKI6 cells were investigated, staining of CA9 and Cadherin 6 was not reliable (Figure 2B and C), consistent with the low expression of both markers in ACHN3 and CAKI6 cells (Figure 1). Unspecific background staining was shown to be <0.008% (data not shown) from isotype control, thus indicating a very low level of false positives.

Stability of assay. As RCC4 expresses all of the three tumour-associated antigens with reliable detections (Figures 2 and 3), and RCC4 cells are of carcinoma origin that constitutes ~90% of all renal cancer cases, we continued to focus on this cell line for evaluation of the assay. Next, we set out to analyse the intra- and inter-assay variability by using the spiking experiments. Before analysis, samples were split into 10 aliquots and analysed separately for intra-assay variability. In addition, each sample

![Figure 1](https://example.com/figure1.jpg)

Figure 1. Flow cytometric detection of the three tumour-associated markers CK18, CA9, and Cadherin 6 in three different renal cancer cell lines, RCC4, ACHN3, and CAKI6. The y axis was set to show for the count of positive events. Gating for positive events was made based on isotype controls.
was reanalysed after \( \sim 8 \) h for inter-assay variability. The results of the two acquisitions showed that the intra-assay coefficient of variance (CV) was \(<16\%\), indicating that the detection is reliable (Table 1).

The inter-assay variability between two time point acquisitions was analysed using linear regression. Percentage of acquired cells from the first run vs percentage of acquired cells from the second run was evaluated. The correlation coefficient \( R^2 \) fell into the range of \( 0.9996–1 \), and thus the correlation between acquisitions was significant for all the three markers (Figure 4). We conclude that detection of CK18, CA9, and Cadherin 6 is stable and consistent with small variations in between experiments.

Figure 2. Flow cytometric detection of cancer cells by staining for the tumour-associated cell surface markers CA9 and Cadherin 6, and the intracellular marker CK18. Cultured cancer cells were spiked to PBMCs at a concentration of 1%, and three-fold stepwise dilution series were prepared, resulting in concentrations of 1%, 0.33%, and 0.11%. Samples of PBMCs alone were used to detect background staining. The percentages show the amount of positive events for staining of the renal cancer cell line RCC4, visualised by plotting each marker (x axis) vs SSC properties (y axis) and gated based on isotype control (A). The same experiment was carried out by analysing the additional cell line CAKI6 (B) and ACHN3 respectively (C) respectively.
Detection of metastatic cells in sentinel lymph nodes by flow cytometry. To explore a possibility of forthcoming clinical benefit for flow cytometry and CK18, CA9, and Cadherin 6 detection of metastatic renal cell tumours, we investigated freshly retrieved single cells from sentinel lymph nodes from renal tumours patients. Preoperative patient characteristics are listed in Table 2.

In patient 1, three SNs (SN1, 2, and 3) were investigated by flow cytometry analysis. There was presence of Cadherin 6-positive cells in SN1, SN2, and SN3 (0.36%, 3.4%, and 0.54%, respectively; Figure 5A). This indicates that all the nodes were positive for metastatic cells. However, no expression of CK18 was noted in any of the nodes (Table 3). As all of the investigated sentinel lymph nodes contained metastases, the patient was classified as TNM stage III.

Two non-SNs (nonSN1 and 2) were identified in patient 2. In nonSN1, we could not detect any positive cells for the three markers, indicating that nonSN1 was free from metastasis (Table 3). However, 0.51% of the cells were positive for CA9 in nonSN2 (Figure 5B) but no positive CK18 and Cadherin 6 cells were detected (Table 3). When we stained the isolated tumour-infiltrating lymphocytes (TILs) from the primary tumour, we could detect 24.07% CK18-positive tumour cells (Figure 5B). The detected cells in TILs were viable tumour cells after enzymatic processing with collagenase and hyaluronidase for TIL isolation.
In patient 3, we analysed four SNs (SN1, SN2, SN3, and SN4) and one non-sentinel node (nonSN1) (Table 3). In SN2 and nonSN1, 3.5% and 0.47% CA9-positive cells were detected, respectively, consistent with the presence of 3.44% Cadherin 6-positive cells in SN2 and 0.26% Cadherin 6-positive cells in nonSN1. Thus, the presence of metastasis in these nodes was concluded. In SN4, we could also detect 0.05% CA9-positive cells, indicating the presence of MICs in this node (Table 3). Thus, this patient is classified as TNM stage III as well.

Three nodes were extracted from patient 4 and two nodes were analysed (SN2 and nonSN1) (Table 3). In SN2, we could detect 0.26% Cadherin 6-positive cells and 1.45% CA9-positive cells, marking the presence of MIC in this node. However, nonSN1 did not show any positive cells for the three tumour cell markers (Table 3).

In patient 5, three nonSNs were identified (nonSN1, nonSN2, and nonSN3). From flow cytometry analysis of the three tumour markers, none of these nodes were shown to have MIC (Table 3 and Figure 5C).

Pathology examination of investigated nodes. Head-to-head comparisons were done per patient between the analysis from flow cytometry and the standard pathology examination. The comparisons between the two methods are listed in Table 4.

The standard anatomical pathology evaluation by H&E from the renal cancer patient no. 1 showed RCC with clear cell type and nuclear characteristics of Fuhrman grade II. The tumour size was >7 cm with no signs of intravascular extension and growth, indicating pT2. All three sentinel lymph nodes identified (SN1, SN2, and SN3) were also analysed by H&E and they showed no signs of metastasis in the investigated lymph nodes (pN0). Thus, from the pathology report, the TNM staging of RCC in this patient is stage II; contradicting to our flow cytometry detection.

In patient 2, standard pathology examination was carried out after nephrectomy. It revealed the tumour being a renal oncocytoma. The two identified nonSNs (nonSN1 and nonSN2) also underwent analysis and subsequently were non-metastatic by H&E.

The results of H&E examination of patient 3 showed the characteristics of mucinous tubular and spindle cell type of RCC. The tumour size was measured to be >7 cm and limited to the kidney (pT2). As this type of RCC has a rare incidence, further IHC examination was carried out that confirmed the diagnosis of mucinous tubular and spindle cell type of RCC. Pathology examination for the identified nodes was also done (SN1, SN2, SN3, SN4, and nonSN1) and showed no signs of metastasis in the investigated nodes. Therefore, based on routine pathology, this patient is in stage II.

The standard pathology examination revealed the tumour size of >7 cm and limited to the kidney (pT2) in patient 4. The tumour was categorised as papillary renal cancer type 1 with some areas of clear cell with nuclear characteristics of Fuhrman grade II. The two nodes extracted (SN2 and nonSN1) were also examined and they showed no positive metastasis (pN0). This concluded that patient 4 is in stage II.

In patient 5, pathology examination was done and showed that the tumour size was >7 cm with breakthrough to the fat capsule without vascular invasion (pT3a). The tumour was characterised as Fuhrman grade II clear cell cancer. The pathology revealed no metastasis from the three investigated nonSNs (nonSN1, nonSN2, and nonSN3) indicating pN0.

**DISCUSSION**

In this study we have, for the first time, investigated markers expressed by renal tumour cells by flow cytometry in order to identify ectopic presence of metastatic cells in lymph nodes. We demonstrate that renal cancer cells can be detected at very low cell counts. The detection method is sensitive and reproducible with low intra- and inter-assay variability. Flow cytometry offers several advantages as compared with the gold standard for evaluation of lymph node status in cancer staging. First, flow cytometry is quick and reliable and can be carried out without extensive resources. Moreover, objective analyses of multiple samples can be performed by a technician.

Earlier attempts have been made to describe detection of tumour cells by different kinds of spiking experiments. In this study we carried out spiking experiments using three separate renal cancer cell lines using the same assay. Our results demonstrate that different markers display varying expression (Figure 1). The staining of intracellular cytokeratin demonstrated the most stable expression in the three cell lines, but caused a slightly higher background. However, background staining can potentially be minimised by using additional washes and more optimised staining conditions. Moreover, when samples are compared with isotype control, the unspecific staining is not a problem as it can be deducted. The assay has a very low s.d. for intra-assay variability, in the range of 0.001–0.04% (Table 1), for expected number of positive cells. Thus, a very small event count above threshold can be considered as indicative for metastasis.

The International Union Against Cancer defines tumour deposits between 0.2 and 2 mm as MICs and clusters and single-cell infiltrations below this cutoff as isolated tumour cells (ITCs) (Heremanek et al., 1999). Assuming a lymph node is ~10 × 5 × 5 mm in size, a MIC of 2 mm equals ~1.6% of the total number of cells in an average lymph node. Accordingly, a MIC of 0.2 mm equals ~0.032% of the total number of cells. From our spiking experiments, we can distinguish a sample that has been spiked with 0.011% of RCC4 cancer cell lines from a control sample with PBMCs only (Figure 2), indicating that the method is stable and sensitive enough to detect MICs. As demonstrated in our verification experiments with SNs and nonSNs from renal tumour patients, we detected the presence of positive cancer cells in both SNs and nonSNs that range from 0.036 to 3.5% in eight nodes from all of the five patients. Six of these nodes fulfilled the criteria to be MICs with positive cells falling in the range of 0.03–1.6% (Table 3). However, these results were contradicted with the pathology examination results, as investigation of H&E sections of the lymph nodes were negative. The number of sections investigated was following routine pathology; it is likely that the investigated sections were not representative for the whole lymph node. Thus, the flow cytometry-based investigation demonstrated MICs and changed the TNM staging group from II to III. This might result in a different therapy regimen and prognosis of the patients, in which further clinical evaluations are needed.

In patient 5, we demonstrated the presence of positive cells in the range of 0.004–0.03% that falls under the criteria of ITCs (Table 3). However, the clinical significance of ITCs is still under debate. It has not clearly been shown whether detection of ITCs in lymph nodes has a clinical impact. In a retrospective study, Joyce

---

**Table 2. Patient characteristics**

| Patients | Gender | Age (years) | Side | cT stage | cN stage |
|----------|--------|-------------|------|----------|----------|
| 1        | M      | 64          | Left | T2       | N0       |
| 2        | F      | 47          | Right| T2       | N0       |
| 3        | F      | 69          | Left | T2       | N0       |
| 4        | F      | 69          | Left | T2       | N0       |
| 5        | M      | 54          | Right| T3       | N0       |

Abbreviations: F = female, M = male.

---
Joyce et al. (2012) showed that the presence of MICs in SNs from patients with breast cancer was associated with axillary disease in 21% of cases, thus predicting metastatic disease. However, the presence of ITCs in the same cohort did not lead to upstaging (Joyce et al., 2012). Reed et al. (2009) made the same conclusion from a prospective cohort and also showed that the presence of MICs, but not ITCs, was a predictor of distant recurrence. As our flow cytometry assay is sensitive enough to detect even ITCs, we...
conclude that the method is noninferior to IHC in detecting metastatic disease of clinical importance.

One interesting finding in our experiments is the detection of CA9-positive cells (0.51%) in nonSN2 of patient 2, in which the patient was diagnosed with renal oncocytoma. We have demonstrated that the background staining of CA9 marker was low (0.002%) (Figure 2A), proving low possibility of false positive. Renal oncocytoma (RO) is a benign epithelial-derived neoplasm in the kidney (Lopez-Beltran et al, 2009). Although benign in nature, there are some reports regarding metastasis of RO (Perez-Ordonez et al, 1997; Oxley et al, 2007), even though it is rare. Other reports also suggest the possible diagnostic uncertainty in differentiating

### Table 3. Detection of cancer cells in patient nodes

| Patients | Samples | Antigen stained | Positive cells (%) | Isotype control (%) | Definite positive cells (%) |
|----------|---------|-----------------|--------------------|---------------------|----------------------------|
| Patient 1 | SN1     | CK18            | 0.53               | 0.88                | 0                          |
|          |         | CA9             | 0.35               | 0.32                | 0.03                       |
|          |         | Cadherin 6      | 0.73               | 0.37                | 0.36                       |
|          | SN2     | CK18            | 0.25               | 0.88                | 0                          |
|          |         | CA9             | 0.14               | 0.32                | 0                          |
|          |         | Cadherin 6      | 3.77               | 0.37                | 3.4                       |
|          | SN3     | CK18            | 0.37               | 0.88                | 0                          |
|          |         | CA9             | 0.06               | 0.32                | 0                          |
|          |         | Cadherin 6      | 0.91               | 0.37                | 0.54                       |
| Patient 2 | nSN1    | CK18            | 0.052              | 0.25                | 0                          |
|          |         | CA9             | 0.46               | 0.48                | 0                          |
|          |         | Cadherin 6      | 0.49               | 0.77                | 0                          |
|          | nSN2    | CK18            | 0.18               | 0.25                | 0                          |
|          |         | CA9             | 0.99               | 0.48                | 0.51                       |
|          |         | Cadherin 6      | 0.46               | 0.77                | 0                          |
| Patient 3 | SN1     | CK18            | 3.9                | 6.38                | 0                          |
|          |         | CA9             | 0.58               | 0.69                | 0                          |
|          |         | Cadherin 6      | 0.33               | 0.64                | 0                          |
|          | SN2     | CK18            | 1.24               | 6.38                | 0                          |
|          |         | CA9             | 4.19               | 0.69                | 3.5                       |
|          |         | Cadherin 6      | 4.08               | 0.64                | 3.44                      |
|          | SN3     | CK18            | 3.97               | 6.38                | 0                          |
|          |         | CA9             | 0.68               | 0.69                | 0                          |
|          |         | Cadherin 6      | 0.45               | 0.64                | 0                          |
|          | SN4     | CK18            | 3.42               | 6.38                | 0                          |
|          |         | CA9             | 0.74               | 0.69                | 0.05                      |
|          |         | Cadherin 6      | 0.27               | 0.64                | 0                          |
|          | nSN1    | CK18            | 5.12               | 6.38                | 0                          |
|          |         | CA9             | 1.16               | 0.69                | 0.47                      |
|          |         | Cadherin 6      | 0.9                | 0.64                | 0.26                      |
| Patient 4 | SN2     | CK18            | 0.30               | 1.22                | 0                          |
|          |         | CA9             | 4.19               | 2.74                | 1.45                      |
|          |         | Cadherin 6      | 0.5                  | 0.24                | 0.26                      |
|          | nSN1    | CK18            | 0.17               | 1.22                | 0                          |
|          |         | CA9             | 1.76               | 2.74                | 0                          |
|          |         | Cadherin 6      | 0.09               | 0.24                | 0                          |
| Patient 5 | nSN1    | CK18            | 0.04               | 0.74                | 0                          |
|          |         | CA9             | 0.04               | 0.01                | 0.03                      |
|          |         | Cadherin 6      | 0.03               | 0.04                | 0                          |
|          | nSN2    | CK18            | 0.02               | 0.74                | 0                          |
|          |         | CA9             | 0.002              | 0.01                | 0                          |
|          |         | Cadherin 6      | 0.006              | 0.04                | 0                          |
|          | nSN3    | CK18            | 0.07               | 0.74                | 0                          |
|          |         | CA9             | 0.02               | 0.01                | 0.01                      |
|          |         | Cadherin 6      | 0.044              | 0.04                | 0.004                     |

Abbreviations: CA9 = carbonic anhydrase IX; CK18 = cytokeratin 18; nSN = non-sentinel node; SN = sentinel node.

### Table 4. Patient outcomes

| Patients | pN stage (pathology examination) | pN stage (flow cytometry) | Final histopathology | Total number of obtained SNs | Number of examined SNs | Number of metastatic SNs | Total number of obtained nonSNs | Number of examined nonSNs | Number of metastatic nonSNs |
|----------|---------------------------------|---------------------------|----------------------|------------------------------|------------------------|--------------------------|-------------------------------|---------------------------|-----------------------------|
| 1        | pN0                             | pN1                       | RCC                  | 5                            | 3                      | 3                        | 0                             | 0                         | 0                           |
| 2        | pN0                             | pN1                       | Oncocytoma           | 0                            | 0                      | 0                        | 2                             | 2                         | 1                           |
| 3        | pN0                             | pN1                       | Muc. spindle         | 4                            | 4                      | 2                        | 1                             | 1                         | 1                           |
| 4        | pN0                             | pN1                       | PRCC                 | 2                            | 1                      | 1                        | 1                             | 1                         | 0                           |
| 5        | pN0                             | pN0                       | RCC                  | 0                            | 0                      | 0                        | 3                             | 3                         | 0                           |

Abbreviations: Muc. = mucinous; nonSN = non-sentinel node; PRCC = papillary renal carcinoma with clear cell type; RCC = renal cell carcinoma with clear cell type; SN = sentinel node.
The authors declare no conflict of interest.

REFERENCES

Amin MB, Crotty TB, Tickoo SK, Farrow GM (1997) Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases. Am J Surg Pathol 21: 1–12.

Benoy IH, Elst H, Van Dam P, Scharpê S, Van Marck E, Vermeulen PB, Dirix LY (2006) Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time. Clin Chem Lab Med 44: 1082–1087.

Bex A, Vermeeren L, Meinhardt W, Prevoo W, Horenblas S, Valdes Olmos RA (2005) Cadherin-6 gene expression in conventional renal cell carcinoma: a useful marker to detect circulating tumor cells. Anticancer Res 25: 377–381.

Lei G, Passosbaco-Faure K, Lambert C, Gentil-Perret A, Lambert C, Genin C, Tostain J (2005) Cadherin-6 gene expression in conventional renal cell carcinoma: a useful marker to detect circulating tumor cells. Anticancer Res 25: 377–381.

Lopez-Beltran A, Carrasco J, Cheng L, Scarpelli M, Kirkali Z, Montironi R (2009) 2009 update on the classification of renal epithelial tumors in adults. Int J Urol 16: 432–443.

Marits P, Karlsson M, Dahl K, Larsson P, Wanders A, Thörn M, Winqvist O (2006) Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br J Cancer 94: 1478–1484.

Marshall FF (2005) The level of cadherin-6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma. J Urol 173: 1919.

Messai Y, Noman MZ, Deroiche A, Kourda N, Akalay I, Hasmim M, Stasik I, Ben Jilani S, Chebil M, Azaïrnaire B, Gati A, Ben Ammar Elgaided A, Chouaib S (2010) Cytokeratin 18 expression pattern correlates with renal cell carcinoma progression: relationship with Snail. Int J Oncol 36: 1145–1154.

Ng KL, Rajandram R, Morais C, Yap NY, Samarutunga H, Gobe GC, Wood ST (2014) Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem? J Clin Pathol 67: 97–104.

Osley JD, Sullivan J, Mitchelmore A, Gillatt DA (2007) Metastatic renal oncocytoma. J Clin Pathol 60: 720–722.

Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gillitiz B, Beldegrun AS, Figlin RA (2003) Renal cell carcinoma with retroperitoneal micrometastases do not predict relapse in stage II colon cancer. J Clin Oncol 21: 871–883.

Red J, Rosman M, Verbancak NM, Mannie A, Cheng Z, Tafra L (2009) Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg 208: 333–340.

Sherif AM, Eriksson E, Thorn M, Vasko J, Riklund K, Ohberg L, Ljungberg B (2012) Sentinel node detection in renal cell carcinoma. A feasibility study for detection of tumour-draining lymph nodes. BJU Int 109: 1134–1139.

Soyupak B, Ergödoğer S, Ergin M, Seydaoğlu G, Kuzgunbay B, Tansu Z (2005) CA9 expression as a prognostic factor in renal clear cell carcinoma. J Urol 174: 68–73.

Tschmelitsch J, Klimstra DS, Cohen AM (2000) Lymph node micrometastases do not predict relapse in stage II colon cancer. Ann Surg Oncol 7: 601–608.

Ulmer AJ, Scholz W, Ernst M, Brandt E, Flad HD (1984) Isolation and subfractionation of human peripheral blood mononuclear cells (PBMC) by density gradient centrifugation on Percoll. Immunobiology 166: 238–250.

Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM (2001) Lack of retroperitoneal lymphadenopathy...
predicts survival of patients with metastatic renal cell carcinoma. 

Weaver DL, Krag DN, Manna EA, Ashikaga T, Harlow SP, Bauer KD (2003) Comparison of pathologist-detected and automated computer-assisted image analysis detected sentinel lymph node micrometastases in breast cancer. *Mod Pathol* 16: 1159–1163.

Weigelt B, Verduijn P, Bosma AJ, Rutgers EJ, Peterse HL, van’t Veer LJ (2004) Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. *Br J Cancer* 90: 1531–1537.

Yusenko MV (2010) Molecular pathology of renal oncocytoma: a review. *Int J Urol* 17: 602–612.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.